Antibodies
2 April 2017
Mersana Therapeutics Presents Preclinical Data on XMT-1522 Supporting Efficacy and Tolerability30 March 2017
Phase II Study of Daratumumab in Non-Hodgkin’s Lymphoma Will Not Proceed to Stage 2 of Trial30 March 2017
FDA Grants Priority Review For Amgen’s BLINCYTO® (blinatumomab) Supplemental Biologics License Application29 March 2017
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis28 March 2017
Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program27 March 2017
Apeiron Biologics receives green light for marketing approval of a neuroblastoma immuntherapy in the European Union24 March 2017
European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases24 March 2017
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris24 March 2017
FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma23 March 2017
Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports